Strategic Partnership Targets U.S. Market Expansion of Superficial Radiotherapy Systems into Hospital-Based and Freestanding Oncology Centers

BOCA RATON, Fla.--(BUSINESS WIRE)--Jun. 26, 2025-- Sensus Healthcare, Inc. (Nasdaq: SRTS) (Sensus or the Company),a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it has entered into a strategic agreement with Radiology Oncology Systems (ROS) to serve as the Company’s primary distribution partner for the U.S. radiation oncology market. Under the terms of the agreement, ROS will be responsible for selling Sensus’s superficial radiotherapy (SRT) systems, including the SRT-100™ and the SRT-100 Vision™, to hospital-based radiation oncology departments and freestanding oncology centers nationwide.

Led by President and CEO John Vano, ROS brings nearly three decades of experience and deep-rooted relationships across radiation oncology, including familiarity with the SRT machines. This new partnership will leverage ROS’s extensive presence across all 50 states to accelerate adoption of Sensus’s image-guided, non-invasive radiotherapy technologies within the oncology continuum of care. Initial orders under the agreement are expected as early as the fourth quarter of 2025, with the potential to expand the distribution agreement to select international markets in the future.

“The benefits of our SRT systems are increasingly being recognized by largely untapped markets outside our core focus on dermatology, and we’re excited to partner with ROS as we deepen our penetration into the hospital-based oncology market,” said Joe Sardano, Chairman and CEO of Sensus Healthcare. “John and his team have an excellent reputation for delivering value and reliability to radiation oncology departments and clinics. We believe this collaboration will meaningfully accelerate the placement of SRT systems into cancer centers that are seeking non-invasive solutions with excellent aesthetic outcomes and minimal disruption to clinical workflows.”

“Sensus’s SRT platform represents an important and growing modality within radiation oncology. By integrating these systems into hospital settings and outpatient oncology centers, we can help providers offer more flexible treatment options while enhancing overall workflow efficiency, patient access and customer satisfaction. We’re proud to bring our commercial infrastructure to this partnership and look forward to working closely with the Sensus team to bring SRT to more oncology practices across the country,” commented Mr. Vano.

This partnership marks another step in Sensus’s strategy to expand beyond dermatology and into hospital and multidisciplinary oncology environments. The Company continues to invest in commercialization and reimbursement initiatives to support broader adoption of its superficial radiation technologies across priority markets.

About Sensus Healthcare

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

Forward-Looking Statements

This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “approximately,” "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.

Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release, as a result of the following factors, among others: the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; the performance of the Company’s information technology systems and its ability to maintain data security; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250626809602/en/

Alliance Advisors IR
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614

Source: Sensus Healthcare, Inc.